Working… Menu

Study to Improve Partner Services for STD Prevention

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00207467
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : September 21, 2005
Tulane University
Information provided by:
Centers for Disease Control and Prevention

Brief Summary:
The goal of this study was to examine the efficacy of patient-delivered partner treatment (PDPT) compared to standard partner referral (PR) and booklet enhanced partner referral (BEPR).

Condition or disease Intervention/treatment Phase
Trichomonas Vaginalis Urethritis Behavioral: Patient-delivered partner treatment Behavioral: Booklet-enhanced partner referral Phase 2

Detailed Description:

For partner treatment, index women who were diagnosed with trichomonas vaginalis and index men who were diagnosed with urethritis were randomized to one of three study arms:

Standard partner referral (PR) – index patients were instructed to tell their partners that they need to go to a clinic for STI evaluation and treatment.

Booklet-enhanced partner referral (BEPR) – index patients were given a wallet-sized booklet containing 4 tear-out cards with information for the partner and treatment guidelines for the providers that would see the partners. The partners could then present this card at a clinic to help the clinician better treat them. If index patients had more than 4 partners, they were given additional booklets.

Patient delivered partner treatment (PDPT) – index patients were given packages containing 2 gram metronidazole (for TV patients) or azithromycin 1 gram and cefixime 400 mg (for urethritis patients) for up to 4 identified sex partners. When cefixime was no longer available, ciprofloxacin 500 mg was used. These packages contained written instructions about how to take the medication, warnings about side effects and a nurse’s pager number to call if there were any questions or if the partner encountered any problems. All medications were distributed in containers with childproof caps and the partner’s initial and birthdates were written on the bottle. This was a requirement of the Louisiana State Pharmacy Board. Names were not documented on the index patient's study or medical records.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 1500 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Prospective Study for Cost-Effectiveness Strategies to Improve Partner Notification: Female Trichomonas and Male Urethritis Studies
Study Start Date : December 2001
Study Completion Date : December 2004

Primary Outcome Measures :
  1. Index patient report of partner taking medicine at 6-8 weeks

Secondary Outcome Measures :
  1. Index patient re-infection at 6-8 weeks
  2. Cost effectiveness outcomes

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   16 Years to 44 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Woman attending Family Planning Clinic or men attending STD clinic
  • Aged 16-44
  • (non-pregnant women) – positive InPouch for trichomonas, or
  • (pregnant women) – positive wet mount or InPouch for Trichomonas vaginalis
  • (men) a complaint of urethritis which is verified on examination
  • Report having >= 1sex partners in past 60 days
  • Not presumptively treated for trichomonas (women) or urethritis (men)
  • Provide informed consent to be re-contacted by telephone or in person in 14-28 days for a follow-up interview and T vaginalis or CT/GC rescreening

Exclusion Criteria:


  • Prisoner
  • Has taken cefixime or azithromycin in last two weeks
  • Has previously participated in the study
  • All female partners are pregnant and did not have male partners Women
  • client has taken metronidazole in the last two weeks
  • client has been in this study previously
  • women who are asymptomatic and in their first trimester of pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00207467

Layout table for location information
United States, Louisiana
Delgado STD Clinic
New Orleans, Louisiana, United States, 99999
Orleans Women's Health Clinic
New Orleans, Louisiana, United States, 99999
Sponsors and Collaborators
Centers for Disease Control and Prevention
Tulane University
Layout table for investigator information
Principal Investigator: Patty Kissinger, PhD Tulane University School of Public Health and Tropical Medicine

Publications of Results:
Layout table for additonal information Identifier: NCT00207467     History of Changes
Other Study ID Numbers: CDC-NCHSTP-3196
CA# R30/CCR619143-01
First Posted: September 21, 2005    Key Record Dates
Last Update Posted: September 21, 2005
Last Verified: September 2005
Keywords provided by Centers for Disease Control and Prevention:
patient-delivered partner treatment
partner referral
sexually transmitted diseases
Additional relevant MeSH terms:
Layout table for MeSH terms
Trichomonas Infections
Protozoan Infections
Parasitic Diseases
Urethral Diseases
Urologic Diseases